GRADE Published: Liraglutide Best for Type 2 Diabetes After Metformin GRADE Published: Liraglutide Best for Type 2 Diabetes After Metformin
The US-funded GRADE trial shows liraglutide performed best overall when added to metformin, followed by insulin glargine, with sitagliptin and glimepiride trailing. But SGLT2 inhibitors were not included in study.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 21, 2022 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news

NPPA fixes price caps for 12 anti-diabetic medicines
These include glimepiride tablet of strength 1 mg, with ceiling price at Rs 3.6 per tablet, while that for 2 mg is Rs 5.72 per tablet. The ceiling price of 1 ml glucose injection of 25 per cent strength has been fixed at 17 paise, while that of 1ml of insulin (soluble) injection of strength 40IU/ml is Rs 15.09. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 25, 2021 Category: Pharmaceuticals Source Type: news

CAROLINA-CARMELINA-Asia-analysis
Cardiovascular and renal safety profile of linagliptin demonstrated in Asian adults with type 2 diabetesIn a sub-analysis of the CAROLINA ® cardiovascular outcome trial, linagliptin demonstrated no increased cardiovascular risk versus glimepiride in Asian adults with type 2 diabetes and high cardiovascular risk1In addition, a sub-analysis of the CARMELINA ® cardiovascular outcome trial demonstrated a similar cardiovascular and renal safety profile for linagliptin versus placebo in Asian adults with type 2 diabetes and high cardiorenal risk2  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 29, 2020 Category: Research Source Type: news

CAROLINA Published: Reaffirms Sulfonylurea Cardiovascular Safety CAROLINA Published: Reaffirms Sulfonylurea Cardiovascular Safety
The study, presented to a European audience of diabetologists at EASD and simultaneously published in JAMA, reaffirms the CV safety of glimepiride, with calls for FDA warning to be removed.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - September 20, 2019 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Linagliptin Noninferior for CV Risk in Early Type 2 Diabetes
THURSDAY, Sept. 19, 2019 -- Linagliptin is noninferior to glimepiride for adults with relatively early type 2 diabetes and elevated cardiovascular risk, according to a study published online Sept. 19 in the Journal of the American Medical... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 19, 2019 Category: Pharmaceuticals Source Type: news

Medical News Today: What to know about glimepiride
Glimepiride is a drug people use to control blood sugar levels in type 2 diabetes. Find out about the potential side effects of glimepiride, and the possible risks of taking this drug. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 23, 2019 Category: Consumer Health News Tags: Diabetes Type 2 Source Type: news

CAROLINA Reassures on CV Safety for Linagliptin, Glimepiride in T2D CAROLINA Reassures on CV Safety for Linagliptin, Glimepiride in T2D
"We think we ' ve vindicated sulfonylureas, at least glimepiride specifically," says an expert, who notes trial findings do inform decision-making, particularly when cost is an issue.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 12, 2019 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news

Full data from CAROLINA ® outcome trial support long-term cardiovascular safety profile of Trajenta®
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced full data from the CAROLINA® trial demonstrating that Trajenta® (linagliptin) did not increase cardiovascular risk compared to glimepiride in adults with type 2 diabetes and cardiovascular risk.(1) The findings were reported today at the American Diabetes Association's 79th Scientific Sessions in San Francisco. (Source: World Pharma News)
Source: World Pharma News - June 11, 2019 Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news

CAROLINA-full-data
Full data from CAROLINA ® outcome trial support long-term cardiovascular safety profile of Trajenta®CAROLINA ® demonstrated no increased cardiovascular risk for Trajenta® (linagliptin) versus glimepiride in the only active-comparator cardiovascular outcome trial for a dipeptidyl peptidase-4 (DPP-4) inhibitor Adults with diabetes treated with Trajenta ® experienced significantly fewer events of hypoglycaemia and a modest weight reduction compared to patients treated with glimepiride Detailed results from CAROLINA ® were presented at the American Diabetes Association’s 79th Scientific Sessions  (Source: Boehringer...
Source: Boehringer Ingelheim Corporate News - June 11, 2019 Category: Research Source Type: news

Boehringer Ingelheim and Lilly announce the CAROLINA(R) cardiovascular outcome trial of Tradjenta(R) met its primary endpoint of non-inferiority compared with glimepiride
Tradjenta (linagliptin) demonstrated no increased cardiovascular risk compared with glimepiride in adults with type 2 diabetes and cardiovascular risk With a median follow-up of more than 6 years, CAROLINA adds evidence to the long-term safety profile o... Biopharmaceuticals, Endocrinology Eli Lilly, Boehringer Ingelheim, Tradjenta, linagliptin, diabetes (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 14, 2019 Category: Pharmaceuticals Source Type: news

Duetact (Pioglitazone Hydrochloride and Glimepiride Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 10, 2018 Category: Drugs & Pharmacology Source Type: news

Amaryl Tablets (Glimepiride) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 4, 2017 Category: Drugs & Pharmacology Source Type: news

Avandaryl (Rosiglitazone Maleate and Glimepiride) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 19, 2016 Category: Drugs & Pharmacology Source Type: news

Expensive New Diabetes Drugs Add Nothing But Cost And Complications
This is the fourth in an ongoing series of blogs exposing the rampant misuse of the medications so aggressively promoted by greedy drug companies. I am very lucky in having the perfect partner in this truth-vs-power effort to contradict Pharma propaganda with evidence based fact. Dick Bijl is President of the International Society of Drug Bulletins (ISDB), an impressive association of 53 national drug bulletins from all around the world, each of which publishes the best available data on the pluses and minuses of different medications. Drug bulletins help patients and doctors see through the misleading misinformation ge...
Source: Science - The Huffington Post - November 17, 2016 Category: Science Source Type: news

Amaryl (glimepiride)
Title: Amaryl (glimepiride)Category: MedicationsCreated: 4/3/1999 12:00:00 AMLast Editorial Review: 9/16/2016 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - September 16, 2016 Category: Endocrinology Source Type: news